Patients with acute myocardial infarction (AMI) complicated with cardiogenic shock (CS) present one of the highest mortality rates recorded in critical care. Mortality rate in this setting is reported around 45-50% even in the most experienced and well-equipped medical centers. The continuous development of ST-segment elevation acute myocardial infarction (STEMI) networks has led not only to a dramatic decrease in STEMI-related mortality, but also to an increase in the frequency of severely complicated cases who survive to be transferred to tertiary centers for life-saving treatments. The reduced effectiveness of vasoactive drugs on a severely altered hemodynamic status led to the development of new devices dedicated to advanced cardiac support. What's more, efforts are being made to reduce time from first medical contact to initiation of mechanical support in this particular clinical context. This review aims to summarize the most recent advances in mechanical support devices, in the setting of CS-complicated AMI. At the same time, the review presents several modern concepts in the organization of complex CS centers. These specialized hubs could improve survival in this critical condition.
INTRODUCTION
The tale of cardiogenic shock (CS) in the setting of acute myocardial infarction (AMI) has long been forgotten.
Many years have passed since anything notable happened with regard to mortality in CS, except for its continuously increased occurrence. Neither the mechanism, nor the treatment of this critical illness have been elucidated. At the same time, inflammation, the defendant of all elusive diseases, has come more and more into the spotlight.
This review aims to summarize the most recent advances in mechanical support devices in the setting of CScomplicated AMI. At the same time, the review presents several modern concepts in the organization of complex CS centers. These specialized hubs could improve survival in this critical condition. Moreover, a significant number of patients who survive to discharge are readmitted in the first 30 days after the acute event, for advanced deterioration of their cardiac status. 6 In the last years, an increasing prevalence of CS has been reported in the STEMI population. It is currently estimated that 7% to 12% of STEMI patients >75 years of age develop CS. [7] [8] [9] The continuous development of STEMI networks has led not only to a dramatic decrease in STEMI-related mortality, but also to an increase in the frequency of severely complicated cases who survive to be transferred to a tertiary center for advanced life-saving treatments. 10 As a result of effective STEMI networks, more and more patients with complex multivessel disease, high-risk coronary lesions or delayed presentation arrive in the catheterization laboratory.
INfLAmmATORY RESPONSE AND AmI-RELATED CS
This leads to a significant increase in the complexity of the cases treated in the acute cardiac care units and in the incidence of CS.
CS is usually diagnosed at the moment of the first medical contact. 
THE ROLE Of CARDIAC CATHETERIzATION LABORATORY IN CS COmPLICATINg AmI
The role of the catheterization laboratory in the treatment of CS is constantly increasing. The "cath lab" is the place of revascularization and, more recently, the scene of initial placement and escalation of MS.
In this study, the group of patients undergoing early revascularization had a significantly reduced mortality at the 6-and 12-month follow-up (50% vs. 37%, p = 0.027 at 6 months and 47% vs. 34%, p = 0.025 at 12 months). thrombus. 16, 17 In recent guidelines, revascularization has gained a Class I indication, while MS only a Class IIa. 4, 15 The 3% increase in mortality recorded between 2005 and 2014 in patients with CS following AMI in the NCDR Cath/ PCI registry is difficult to understand. 18 The incorrect use of MS, the timing of its initiation, and the difference in expertise of the catheterization laboratories involved could explain this increase in mortality. Expertise is generally a key to success, and the volume of activity stands at its base. "Good judgment comes from experience; experience comes from bad judgment" is an aphorism attributed to Dr. Kerr L. White. 19 CS is a severe condition which does not allow bad judgments. A multidisciplinary approach could bring an end to the truth in the quotation above.
REPERfUSION IN CS
It needs to be underlined that reperfusion in CS remains the same important therapeutic step, even if a little delayed by the early insertion of MS. 20 The most frequent anatomic scenario in patients with CS and AMI is rep- in an intra-aortic balloon which inflates during diastole and deflates during systole, being able to decrease ventricular workload and to increase cardiac output. 31 However, the use of IABP in patients with CS complicating AMI failed to demonstrate a significant reduction in 30-day mortality in the IABP-II Shock trial. 32 The recently introduced ECMO devices are also inserted percutaneously, being able to increase coronary, cerebral, and peripheral perfusion and demonstrating a 33% higher survival at 30 days compared with IABP. 33 The third type of percutaneously inserted devices is represented by left ventricular assist devices, the most commonly used types being represented by Impella (implanted using the transaortic route) and TandemHeart (implanted using the transapical route 
THE LEvEL Of CS CENTERS AND mORTALITY
A recent meta-analysis that included 22 PCI and CABG studies demonstrated a significantly lower AMI-related mortality in hospitals with large PCI or CABG volume (>600 cases/year). 14 Similarly, in an intensive cardiac care unit, mortality is directly associated not only to the available facilities, but also to the experience of the involved medical staff. 37, 38 Several recent studies demonstrated the impact of a properly organized intensive care unit on cardiac-related mortality in patients with advanced heart failure. In a study by Na et al., the transition from a model in which a general intensivist provided assistance for critical cardiac patients, to a model in which assistance was provided by dedicated personnel resulted in a significant reduction in mortality from 18% to 12%. 39 In another report, the implementation of high-intensity management in the cardiac critical care unit led by a specialized intensivist, resulted in a decrease in cardiovascular mortality from 6% to 3%. 40 The case volume of the cardiac critical care unit is also important. A comparative study between centers with a low volume versus a high volume of annually treated AMI cases reported significantly lower mortality rates when patients were referred to a high-volume center (11% vs. 4%, p <0.0001 for in-hospital mortality and 7% vs. 3%, p <0.0001 for intensive care unit mortality). 41 These observations are also valid in the case of CS, the most critical condition recorded in a cardiac critical care unit. A statistically significant decrease in overall adjusted mortality was seen in hospitals with high numbers of CS cases. Mortality was 42.0% in centers with less than 27 patients/year compared to 37.0% in centers with more than 107 cases/year. 42 These facts advocate for the establishment of CS care centers with different levels of competence and mandatory multidisciplinary approach. At the base of this concept stands the metrics of FMC-S time.
The aim is to achieve a FMC-S time of less than 90 min in the pre-PCI model of MS insertion. 43 The modern systems of care for CS include a high-volume center acting as a hub, several spoke centers, and an integrated emergency medical system with clearly defined protocols for early diagnosis of CS, prompt initiation of the first therapeutic measures, and immediate transfer to the hub center.
NETwORkS fOR CS COmPLICATINg AmI
The significantly shorten time delays. These protocols can be applied in case of modern "shock networks", on the premise that the extension of the "network-integrated services" model beyond STEMI may bring similar benefits to other acute cardiovascular diseases. [56] [57] [58] [59] [60] FMC is a cornerstone in the triage of patients. At this moment in time, the diagnosis of CS is highly demanding given the multitude of currently used definitions. Transport to a PCI-capable hospital without advanced CS treatment capabilities is acceptable if the estimated FMC-S time exceeds 120 min. As a result, the delay in primary PCI reperfusion will be avoided.
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Transfer to a specialized CS center is mandatory if FMC-S time is less than 120 min. If longer than 120 min, the destination would be a non-shock center catheterization laboratory in view of primary PCI (Figure 1 ). The Detroit protocol can be used and Impella CP inserted if left ventricular end-diastolic pressure exceeds 15 mmHg before the procedure. 43 This initial pressure determination can help the diagnosis of severe pump failure or pre-shock.
As a result of CS definition, some vasoactive support might be used, but the target of systolic blood pressure is merely speculative. Norepinephrine is the first choice, because of fewer side effects compared to dopamine.
The final destination of a patient with CS is a Level 1 CS Center, the most specialized facility in the algorithm proposed by Rab et al. 11 In this algorithm, 
CONCLUSIONS
Like every story worth telling, cardiogenic shock has its heroes and its villains. Mechanical support devices fight the complex, deleterious, interconnected mechanisms of cardiogenic shock and offer the necessary hemodynamic conditions for the primary PCI procedure to take place.
Consequent restoration of coronary blood flow treats the cause of the index event and creates the foundation for the resolution of this high-mortality encumbered condition.
